Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH)

International Urology and Nephrology

Volumn 33, Issue 2, 2001, Pages 217-225

  Preuss, Harry G ^a   Marcusen, Charlyn ^a   Regan, James ^b   Klimberg, Ira W ^c   Welebir, Timothy A ^d   Jones, William A ^d  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^c Urology Center of Florida   (United States)

^d NONE

Author keywords

B sitosterol; Benign prostatic hyperplasia, Natural means to treat; Cernitin; Frequency, Natural means to treat; Nocturia, Natural means to treat; Saw Palmetto

Indexed keywords

ALPHA TOCOPHEROL; CERNITIN; NATURAL PRODUCT; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SABAL EXTRACT; SITOSTEROL; ANTIANDROGEN; BIOLOGICAL PRODUCT; PLANT EXTRACT; SITOSTEROL DERIVATIVE;

ANTIGEN DETECTION; ARTICLE; BLADDER CAPACITY; CANCER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG SAFETY; FREQUENCY ANALYSIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; NEUROLOGIC DISEASE; NOCTURIA; OSTEOPHYTE; PILL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; SABAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOM; SYMPTOMATOLOGY; THORAX PAIN; UNITED STATES; URINE FLOW RATE; PATHOPHYSIOLOGY; RYE; URODYNAMICS;

ANDROGEN ANTAGONISTS; BIOLOGICAL FACTORS; DOUBLE-BLIND METHOD; HUMAN; MALE; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; SITOSTEROLS; SUPPORT, NON-U.S. GOV'T; URODYNAMICS; VITAMIN E; BIOLOGICAL PRODUCTS; HUMANS; SECALE CEREALE; SERENOA;

EID: 0035527529     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015227604041     Document Type: Article

References (27)

1. The therapeutic results of defined pollen extract in patients with chronic prostatitis
2. Conservative treatment of benign prostatic hyperplasia (BPH) with Cernilton N. Results of a placebo-controlled double-blind study
3. Phytotherapy of BPH with Cernilton N. Results of a controlled clinical study
4. Treatment of chronic prostatitis and prostadynia with pollen extract
5. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton. A double-blind, placebo-controlled study
6. Evaluation of cernitin in chronic prostatitis
7. Quantitative evaluation on the effectiveness of Cernilton on benign prostatic hypertrophy
8. The treatment of benign prostatic hyperplasia with phytopharmacia: A comparative study of Cernilton and beta sitosterol
9. Results of treatment with pollen extract (cernilton N) in prostadynia and chronic prostatitis
10. Clinical evaluation of long-term treatment using cernitin pollen extract in patients with benign prostatic hyperplasia
11. Comparison of finasteride (Proscar), a 5α reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α reductase inhibition
12. Inhibition of androgen metabolism and binding by a liposterolic extract of Serenoa repens B in human foreskin fibroblasts
13. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients
14. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia
15. Editorial review of "Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients"
16. The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: A multicenter open study
17. Medical treatment of prostatic adenoma. Controlled trial PA 109 vs placebo in 110 patients
18. A multicenter, placebo-controlled, double-blind clinical trial of B-sitosterol (Phytosterol) for the treatment of benign prostatic hyperplasia
19. Randomized, placebo-controlled clinical trial of B-sitosterol in patients with benign prostatic hyperplasia
20. An inhibitor of 5-alpha-reductase, MK-906 suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia
21. The effect of finasteride in men with benign prostatic hyperplasia
22. Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia
23. Hemmung der arachindonsaurekaskade durch einen extrakt aus roggenpollen
24. Anti-inflammatory activity of sabel fruit extracts prepared with supercritical carbon dioxide